OraSure Technologies
- Home ›
- US ›
- Healthcare
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. The last earnings update was 41 days ago. More info.
Add to Portfolio Compare Print
- OraSure Technologies has significant price volatility in the past 3 months.
OSUR Share Price and Events
7 Day Returns
1 Year Returns
OSUR Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| OraSure Technologies (OSUR) | 3.9% | 4.7% | -23.5% | -49.5% | 30.6% | 2.3% |
| US Medical Equipment | 1.5% | 7.4% | 2.7% | 14.6% | 63.8% | 98.7% |
| US Market | 1.2% | 2% | 2% | 2.3% | 37.9% | 39.8% |
1 Year Return vs Industry and Market
- OSUR underperformed the Medical Equipment industry which returned 14.6% over the past year.
- OSUR underperformed the Market in United States of America which returned 2.3% over the past year.
Value
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current
share
price of
OraSure Technologies
to its discounted cash flow analysis.value.The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Below are the data sources, inputs and calculation used to determine the intrinsic value for OraSure Technologies.
| Data Point | Source | Value |
|---|---|---|
| Valuation Model | 2 Stage Free Cash Flow to Equity | |
| Levered Free Cash Flow | Average of 3 Analyst Estimates (S&P Global) | See below |
| Discount Rate (Cost of Equity) | See below | 8.1% |
| Perpetual Growth Rate | 10-Year US Government Bond Rate | 2.7% |
An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.
| Data Point | Calculation/ Source | Result |
|---|---|---|
| Risk-Free Rate | 10-Year US Govt Bond Rate | 2.7% |
| Equity Risk Premium | S&P Global | 6% |
| Medical Equipment Unlevered Beta | Simply Wall St/ S&P Global | 0.85 |
| Re-levered Beta | = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.852 (1 + (1- 21%) (1%)) |
0.905 |
| Levered Beta | Levered Beta limited to 0.8 to 2.0 (practical range for a stable firm) |
0.91 |
| Discount Rate/ Cost of Equity |
= Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (0.905 * 5.96%) |
8.13% |
Discounted Cash Flow Calculation for NasdaqGS:OSUR using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for OraSure Technologies is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.
| Levered FCF (USD, Millions) | Source |
Present Value Discounted (@ 8.13%) |
|
|---|---|---|---|
| 2019 | 25.40 | Analyst x1 | 23.49 |
| 2020 | 26.60 | Analyst x1 | 22.75 |
| 2021 | 27.68 | Est @ 4.04% | 21.89 |
| 2022 | 28.69 | Est @ 3.65% | 20.99 |
| 2023 | 29.65 | Est @ 3.37% | 20.06 |
| 2024 | 30.60 | Est @ 3.18% | 19.15 |
| 2025 | 31.53 | Est @ 3.05% | 18.25 |
| 2026 | 32.46 | Est @ 2.95% | 17.37 |
| 2027 | 33.39 | Est @ 2.88% | 16.53 |
| 2028 | 34.34 | Est @ 2.84% | 15.72 |
| Present value of next 10 years cash flows | $196.22 | ||
| Calculation | Result | |
|---|---|---|
| Terminal Value |
= FCF2028
× (1 + g) ÷ (Discount Rate – g)
= $34.34 × (1 + 2.73%) ÷ (8.13% – 2.73%) |
$653.92 |
| Present Value of Terminal Value |
= Terminal Value ÷ (1 + r)10
= $653.92 ÷ (1 + 8.13%)10 |
$299.41 |
| Calculation | Result | |
|---|---|---|
| Total Equity Value |
= Present value of next 10 years cash flows +
Terminal Value
= $196.22 + $299.41 |
$495.62 |
| Equity Value per Share (USD) |
= Total value / Shares Outstanding
= $495.62 / 62.05 |
$7.99 |
| Calculation | Result | |
|---|---|---|
| Value per share (USD) | From above. | $7.99 |
| Current discount | Discount to share price of
$8.84
= -1 x ($8.84 - $7.99) / $7.99 |
-10.7% |
Learn more about our DCF calculations in Simply Wall St’s analysis model .
- The current share price of OraSure Technologies is above its future cash flow value.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for OraSure Technologies's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
OraSure Technologies's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2019-03-31) in USD | $0.31 |
| NasdaqGS:OSUR Share Price ** | NasdaqGS (2019-06-19) in USD | $8.84 |
| United States of America Medical Equipment Industry PE Ratio | Median Figure of 64 Publicly-Listed Medical Equipment Companies | 41.06x |
| United States of America Market PE Ratio | Median Figure of 3,092 Publicly-Listed Companies | 17.87x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of OraSure Technologies.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = NasdaqGS:OSUR Share Price ÷ EPS (both in USD) = 8.84 ÷ 0.31 |
28.13x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- OraSure Technologies is good value based on earnings compared to the US Medical Equipment industry average.
- OraSure Technologies is overvalued based on earnings compared to the United States of America market.
Price based on expected Growth
Does
OraSure Technologies's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | 28.13x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts |
17.7%per year |
| United States of America Medical Equipment Industry PEG Ratio | Median Figure of 55 Publicly-Listed Medical Equipment Companies | 2.3x |
| United States of America Market PEG Ratio | Median Figure of 2,128 Publicly-Listed Companies | 1.53x |
*Line of best fit is calculated by linear regression .
| Calculation | Outcome | |
|---|---|---|
| PEG Ratio | = PE Ratio ÷ Net Income Annual Growth Rate = 28.13x ÷ 17.7% |
1.59x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- OraSure Technologies is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on
OraSure Technologies's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2019-03-31) in USD | $4.55 |
| NasdaqGS:OSUR Share Price * | NasdaqGS (2019-06-19) in USD | $8.84 |
| United States of America Medical Equipment Industry PB Ratio | Median Figure of 183 Publicly-Listed Medical Equipment Companies | 4.44x |
| United States of America Market PB Ratio | Median Figure of 5,246 Publicly-Listed Companies | 1.8x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = NasdaqGS:OSUR Share Price ÷ Book Value per Share (both in USD) = 8.84 ÷ 4.55 |
1.94x |
* Primary Listing of OraSure Technologies.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- OraSure Technologies is good value based on assets compared to the US Medical Equipment industry average.
Value checks
We assess OraSure Technologies's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check) OraSure Technologies has a total score of 2/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
Future Performance
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- OraSure Technologies's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
- OraSure Technologies's earnings growth is expected to exceed the United States of America market average.
- OraSure Technologies's revenue growth is positive but not above the United States of America market average.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| NasdaqGS:OSUR Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts | 17.7% |
| NasdaqGS:OSUR Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts | 6.4% |
| United States of America Medical Equipment Industry Earnings Growth Rate | Market Cap Weighted Average | 22% |
| United States of America Medical Equipment Industry Revenue Growth Rate | Market Cap Weighted Average | 7.9% |
| United States of America Market Earnings Growth Rate | Market Cap Weighted Average | 13.9% |
| United States of America Market Revenue Growth Rate | Market Cap Weighted Average | 7.4% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (2 months ago) | See Below |
| Future Estimates | Average of up to 3 Analyst Estimates (S&P Global) | See Below |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2021-12-31 | 198 | 25 | 1 | |
| 2020-12-31 | 185 | 33 | 21 | 3 |
| 2019-12-31 | 173 | 32 | 14 | 3 |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2019-03-31 | 167 | 32 | 19 |
| 2018-12-31 | 180 | 39 | 20 |
| 2018-09-30 | 178 | 23 | 17 |
| 2018-06-30 | 176 | 20 | 15 |
| 2018-03-31 | 175 | 23 | 16 |
| 2017-12-31 | 166 | 28 | 31 |
| 2017-09-30 | 145 | 30 | 31 |
| 2017-06-30 | 135 | 30 | 31 |
| 2017-03-31 | 126 | 32 | 30 |
| 2016-12-31 | 123 | 25 | 20 |
| 2016-09-30 | 125 | 26 | 17 |
| 2016-06-30 | 123 | 36 | 12 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (2 months ago) | See Below |
| Future Estimates | Average of up to 3 Analyst Estimates (S&P Global) | See Below |
All data from OraSure Technologies Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2021-12-31 | 0.39 | 0.39 | 0.39 | 1.00 |
| 2020-12-31 | 0.34 | 0.37 | 0.30 | 3.00 |
| 2019-12-31 | 0.23 | 0.23 | 0.23 | 3.00 |
| Date (Data in USD Millions) | EPS * |
|---|---|
| 2019-03-31 | 0.31 |
| 2018-12-31 | 0.33 |
| 2018-09-30 | 0.29 |
| 2018-06-30 | 0.25 |
| 2018-03-31 | 0.27 |
| 2017-12-31 | 0.52 |
| 2017-09-30 | 0.53 |
| 2017-06-30 | 0.55 |
| 2017-03-31 | 0.53 |
| 2016-12-31 | 0.35 |
| 2016-09-30 | 0.31 |
| 2016-06-30 | 0.22 |
*GAAP earnings excluding extraordinary items.
Performance in 3 years
In the same way as past performance we look at the future estimated return
(profit) compared to the available
funds. We do this looking forward 3 years.
- Unable to establish if OraSure Technologies will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
Future performance checks
We assess OraSure Technologies's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
OraSure Technologies has a total score of 2/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
Past Performance
How has OraSure Technologies performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- OraSure Technologies has delivered over 20% year on year earnings growth in the past 5 years.
- OraSure Technologies's 1-year earnings growth is less than its 5-year average (17.5% vs 42.1%)
- OraSure Technologies's earnings growth has not exceeded the US Medical Equipment industry average in the past year (17.5% vs 31.9%).
Earnings and Revenue History
All data from OraSure Technologies Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2019-03-31 | 167.49 | 19.26 | 59.27 | 16.55 |
| 2018-12-31 | 180.04 | 20.40 | 58.13 | 16.25 |
| 2018-09-30 | 178.29 | 17.41 | 58.93 | 16.02 |
| 2018-06-30 | 175.85 | 15.08 | 59.20 | 15.39 |
| 2018-03-31 | 175.29 | 16.39 | 58.37 | 14.47 |
| 2017-12-31 | 166.38 | 30.95 | 57.85 | 13.37 |
| 2017-09-30 | 144.88 | 30.83 | 59.71 | 10.03 |
| 2017-06-30 | 135.04 | 31.31 | 58.95 | 10.00 |
| 2017-03-31 | 126.22 | 29.72 | 57.44 | 9.64 |
| 2016-12-31 | 122.80 | 19.72 | 58.01 | 9.75 |
| 2016-09-30 | 125.08 | 17.14 | 57.96 | 10.76 |
| 2016-06-30 | 122.69 | 12.37 | 61.23 | 10.09 |
| 2016-03-31 | 121.72 | 10.50 | 62.46 | 10.10 |
| 2015-12-31 | 119.72 | 8.17 | 61.06 | 11.17 |
| 2015-09-30 | 116.02 | 0.90 | 62.81 | 12.13 |
| 2015-06-30 | 114.00 | 0.57 | 61.03 | 12.59 |
| 2015-03-31 | 110.02 | 1.13 | 62.30 | 12.37 |
| 2014-12-31 | 106.46 | -4.61 | 65.27 | 11.66 |
| 2014-09-30 | 106.55 | 4.25 | 65.90 | 9.85 |
| 2014-06-30 | 103.38 | 1.22 | 65.39 | 9.53 |
| 2014-03-31 | 101.31 | -6.60 | 66.52 | 9.46 |
| 2013-12-31 | 98.94 | -11.19 | 68.72 | 10.33 |
| 2013-09-30 | 92.32 | -23.27 | 67.98 | 11.10 |
| 2013-06-30 | 89.76 | -23.81 | 67.48 | 11.43 |
| 2013-03-31 | 88.04 | -22.09 | 65.23 | 11.85 |
| 2012-12-31 | 87.82 | -15.12 | 59.91 | 11.94 |
| 2012-09-30 | 89.36 | -9.13 | 54.64 | 12.54 |
| 2012-06-30 | 88.96 | -10.62 | 50.57 | 15.09 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- OraSure Technologies has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
- OraSure Technologies used its assets less efficiently than the US Medical Equipment industry average last year based on Return on Assets.
- OraSure Technologies has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
Past performance checks
We assess OraSure Technologies's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
OraSure Technologies has a total score of 2/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
Health
How is OraSure Technologies's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up OraSure Technologies's finances.
The net worth of a company is the difference between its assets and liabilities.
- OraSure Technologies is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- OraSure Technologies's cash and other short term assets cover its long term commitments.
Balance sheet
Assets
Liabilities and shares
- Low level of unsold assets.
- Debt is covered by short term assets, assets are 155.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from OraSure Technologies Company Filings, last reported 2 months ago.
| Date (Data in USD Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2019-03-31 | 280.51 | 5.49 | 146.99 |
| 2018-12-31 | 283.38 | 0.00 | 156.57 |
| 2018-09-30 | 276.75 | 0.00 | 150.34 |
| 2018-06-30 | 265.17 | 0.00 | 145.32 |
| 2018-03-31 | 258.72 | 0.00 | 143.49 |
| 2017-12-31 | 258.08 | 0.00 | 154.06 |
| 2017-09-30 | 249.51 | 0.00 | 160.14 |
| 2017-06-30 | 229.41 | 0.00 | 160.23 |
| 2017-03-31 | 208.83 | 0.00 | 139.63 |
| 2016-12-31 | 185.85 | 0.00 | 119.12 |
| 2016-09-30 | 176.48 | 0.00 | 119.34 |
| 2016-06-30 | 168.79 | 0.00 | 113.44 |
| 2016-03-31 | 163.02 | 0.00 | 102.25 |
| 2015-12-31 | 159.44 | 0.00 | 101.32 |
| 2015-09-30 | 160.00 | 0.00 | 108.19 |
| 2015-06-30 | 159.85 | 0.00 | 91.41 |
| 2015-03-31 | 155.83 | 0.00 | 89.49 |
| 2014-12-31 | 158.70 | 0.00 | 97.87 |
| 2014-09-30 | 160.92 | 0.00 | 98.86 |
| 2014-06-30 | 160.32 | 0.00 | 80.27 |
| 2014-03-31 | 154.71 | 0.00 | 84.19 |
| 2013-12-31 | 161.15 | 0.00 | 93.19 |
| 2013-09-30 | 154.89 | 0.00 | 82.59 |
| 2013-06-30 | 154.55 | 0.00 | 76.96 |
| 2013-03-31 | 159.92 | 0.00 | 79.28 |
| 2012-12-31 | 170.32 | 0.00 | 87.89 |
| 2012-09-30 | 174.78 | 0.00 | 89.42 |
| 2012-06-30 | 98.84 | 7.04 | 23.27 |
- OraSure Technologies's level of debt (0.5%) compared to net worth is satisfactory (less than 40%).
- The level of debt compared to net worth has increased over the past 5 years (0% vs 0.5% today).
- Debt is well covered by operating cash flow (2417.4%, greater than 20% of total debt).
- Unable to confirm if the interest payments on OraSure Technologies's debt are well covered by earnings due to lack of past financial data.
Financial health checks
We assess OraSure Technologies's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) OraSure Technologies has a total score of 4/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
Dividends
What is OraSure Technologies's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
$2,000 of
OraSure Technologies
shares you are expected to receive
$0
in your first year as a dividend.
Dividend Amount
- Unable to evaluate OraSure Technologies's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate OraSure Technologies's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 3 Analyst Estimates (S&P Global) | See Below |
| United States of America Medical Equipment Industry Average Dividend Yield | Market Cap Weighted Average of 24 Stocks | 1.2% |
| United States of America Market Average Dividend Yield | Market Cap Weighted Average of 2011 Stocks | 2.4% |
| United States of America Minimum Threshold Dividend Yield | 10th Percentile | 0.8% |
| United States of America Bottom 25% Dividend Yield | 25th Percentile | 1.4% |
| United States of America Top 25% Dividend Yield | 75th Percentile | 3.7% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in $) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2021-12-31 | ||
| 2020-12-31 | ||
| 2019-12-31 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to perform a dividend volatility check as OraSure Technologies has not reported any payouts.
- Unable to verify if OraSure Technologies's dividend has been increasing as the company has not reported any payouts.
Income/ dividend checks
We assess OraSure Technologies's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can OraSure Technologies afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) OraSure Technologies has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
Management
CEO
| COMPENSATION | $2,099,594 |
| AGE | 57 |
| TENURE AS CEO | 1.2 years |
CEO Bio
Dr. Stephen S. Tang, also known as Steve, Ph.D. has been President and Chief Executive Officer at OraSure Technologies, Incorporation since April 01, 2018. Dr. Tang has been Chief Executive Officer and President of University City Science Center since January 2008. Dr. Tang has a wealth of professional experience in academia, professional services and private industry. Most notably, he is the first president in the Science Center's 45-year history to have not only led a company through venture funding and an initial public offering, but to also served as a senior executive with a large life sciences company as it acquired and integrated smaller start-ups. He served as General Manager and Group Vice President for Life Science at Olympus America Inc. from 2006 to 2008 and as Vice President of Life Science Business Development from 2005 to 2006. He joined Olympus in 2005. He served as President and Chief Executive Officer of Millennium Cell Inc. from June 2000 to March 19, 2004 and served as its Acting Chief Financial Officer since February 14, 2003. From January 1996 to June 2000, Dr. Tang served as Vice President and Vice President and Managing Director of the global pharmaceutical and healthcare practice for the management consulting firm A.T. Kearney, Inc., a wholly-owned subsidiary of Electronic Data Systems, Inc., where he directed global business development and marketing. Dr. Tang's extensive business experience and in particular his experience in the life sciences industry and with strategic and business development matters. He served as a Co-Leader, Vice President and Co- Managing Director of the global chemical and environmental practice of Gemini Consulting, Inc., a wholly-owned subsidiary of Cap Gemini. Prior to that, he served as President and Founder of Tangent Technologies, a technical consulting firm to chemical, pharmaceutical and biotechnology companies and senior research engineer and Assistant Director of Lehigh University's Center of Molecular Bioscience and Biotechnology. He served as the Chairman of OraSure Technologies, Inc. since November 14, 2016 until April 01, 2018. He has been a Director of University City Science Center since June 2010, OraSure Technologies, Inc. since April 6, 2011 and Greater Philadelphia Chamber of Commerce since October 2011. He serves as a Director of Neuro Diagnostic Devices, Inc. He serves as Member of the Innovation Advisory Board at United States Department of Commerce. He served as a Director of Millennium Cell Inc. from June 2000 to March 19, 2004. Dr. Tang received his B.S. in Chemistry from College of William and Mary, an M.S. and Ph.D. in Chemical Engineering from Lehigh University and an MBA from Wharton School of Business at University of Pennsylvania.
CEO Compensation
- Steve's compensation has increased by more than 20% in the past year whilst earnings grew less than 20%.
- Steve's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure
Average tenure and age of the OraSure Technologies management team in years:
- The average tenure for the OraSure Technologies management team is less than 2 years, this suggests a new team.
Management Team
Steve Tang
President
$2M
57
1.2 yrs
Roberto Cuca
CFO & Principal Accounting Officer
$1M
50
1 yrs
Jack Jerrett
Senior VP
$973K
59
18.6 yrs
Tony Zezzo
Executive VP & Business Unit Leader of Infectious Disease
$1M
64
2.4 yrs
Brian Smith
Vice Chairman & EVP of Innovation - DNA Genotek
$979K
59
1.8 yrs
Mike Reed
Senior VP of R&D and Chief Science Officer
$779K
49
3.2 yrs
Jeanne Mell
Vice President of Corporate Communications
0.8 yrs
Nancy McLane
Senior Vice President of Operations
Kathy Weber
Executive VP & Business Unit Leader of Molecular Solutions
51
6.6 yrs
David Rappaport
Senior Vice President of Business Development
1.2 yrs
Board of Directors Tenure
Average tenure and age of the OraSure Technologies board of directors in years:
- The tenure for the OraSure Technologies board of directors is about average.
Board of Directors
Mike Celano
Chairman of the Board
$506K
59
1.2 yrs
Steve Tang
President
$2M
57
8.2 yrs
Ronny Lancaster
Independent Director
$170K
66
16.1 yrs
Eamonn Hobbs
Independent Director
$157K
59
3.3 yrs
Aradhana Sarin
Independent Director
$562K
43
1.3 yrs
Chuck Patrick
Independent Director
$169K
63
13.4 yrs
Mara Aspinall
Independent Director
$157K
56
2 yrs
Who owns this company?
Recent Insider Trading
- More shares have been bought than sold by OraSure Technologies insiders in the past 3 months.
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price ($) | Value ($) | |
|---|---|---|---|---|---|---|---|---|---|---|
| 14. May 19 | Buy | Stephen Tang | Individual | 14. May 19 | 14. May 19 | 1,000 | $8.56 | $8,560 | ||
| 14. May 19 | Buy | Jack Jerrett | Individual | 13. May 19 | 13. May 19 | 10,000 | $8.55 | $85,487 | ||
| 14. May 19 | Buy | Roberto Cuca | Individual | 10. May 19 | 10. May 19 | 10,000 | $9.04 | $90,314 | ||
| 29. Aug 18 | Sell | Charles Patrick | Individual | 27. Aug 18 | 27. Aug 18 | -8,000 | $16.29 | $-130,320 | ||
Management checks
We assess OraSure Technologies's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) OraSure Technologies has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
News
Simply Wall St News
Here's What OraSure Technologies, Inc.'s (NASDAQ:OSUR) P/E Ratio Is Telling Us
Check out our latest analysis for OraSure Technologies How Do I Calculate A Price To Earnings Ratio? … The formula for price to earnings is: Price to Earnings Ratio = Share Price ÷ Earnings per Share (EPS) Or for OraSure Technologies: P/E of 27.18 = $8.54 ÷ $0.31 (Based on the year to March 2019.) Is A High Price-to-Earnings Ratio Good? … NasdaqGS:OSUR Price Estimation Relative to Market, June 17th 2019 Its relatively low P/E ratio indicates that OraSure Technologies shareholders think it will struggle to do as well as other companies in its industry classification.
Simply Wall St - – Full articleHave Insiders Been Buying OraSure Technologies, Inc. (NASDAQ:OSUR) Shares?
As Peter Lynch said, 'insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.' Check out our latest analysis for OraSure Technologies The Last 12 Months Of Insider Transactions At OraSure Technologies Over the last year, we can see that the biggest insider sale was by the Independent Director, Charles Patrick, for US$130k worth of shares, at about US$16.29 per share. … OraSure Technologies Insiders Bought Stock Recently Over the last three months, we've seen significant insider buying at OraSure Technologies. … Insider Ownership of OraSure Technologies For a common shareholder, it is worth checking how many shares are held by company insiders.
Simply Wall St - – Full articleEstimating The Intrinsic Value Of OraSure Technologies, Inc. (NASDAQ:OSUR)
Using the most recent financial data, we'll take a look at whether the stock is fairly priced by estimating the company's future cash flows and discounting them to their present value. … Generally we assume that a dollar today is more valuable than a dollar in the future, so we need to discount the sum of these future cash flows to arrive at a present value estimate: 10-year free cash flow (FCF) estimate 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 Levered FCF ($, Millions) $25.40 $26.60 $27.68 $28.69 $29.65 $30.60 $31.53 $32.46 $33.39 $34.34 Growth Rate Estimate Source Analyst x1 Analyst x1 Est @ 4.04% Est @ 3.65% Est @ 3.37% Est @ 3.18% Est @ 3.05% Est @ 2.95% Est @ 2.88% Est @ 2.84% Present Value ($, Millions) Discounted @ 8.29% $23.45 $22.68 $21.79 $20.86 $19.91 $18.97 $18.05 $17.16 $16.30 $15.48 Present Value of 10-year Cash Flow (PVCF)= $194.65m "Est" = FCF growth rate estimated by Simply Wall St After calculating the present value of future cash flows in the intial 10-year period, we need to calculate the Terminal Value, which accounts for all future cash flows beyond the first stage. … Terminal Value (TV) = FCF2029 × (1 + g) ÷ (r – g) = US$34m × (1 + 2.7%) ÷ (8.3% – 2.7%) = US$634m Present Value of Terminal Value (PVTV) = TV / (1 + r)10 = $US$634m ÷ ( 1 + 8.3%)10 = $285.79m The total value is the sum of cash flows for the next ten years plus the discounted terminal value, which results in the Total Equity Value, which in this case is $480.44m.
Simply Wall St - – Full articleIf You Had Bought OraSure Technologies (NASDAQ:OSUR) Shares Five Years Ago You'd Have Made 51%
During the five years of share price growth, OraSure Technologies moved from a loss to profitability. … Given that the company made a profit three years ago, but not five years ago, it is worth looking at the share price returns over the last three years, too. … Indeed, the OraSure Technologies share price has gained 43% in three years.
Simply Wall St - – Full articleWhat You Must Know About OraSure Technologies, Inc.'s (NASDAQ:OSUR) Beta Value
(NASDAQ:OSUR), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … Beta is a widely used metric to measure a stock's exposure to market risk (volatility). … The first thing to understand about beta is that the beta of the overall market is one.
Simply Wall St - – Full articleA Closer Look At OraSure Technologies, Inc.'s (NASDAQ:OSUR) Uninspiring ROE
By way of learning-by-doing, we'll look at ROE to gain a better understanding of OraSure Technologies, Inc. … OraSure Technologies has a ROE of 7.2%, based on the last twelve months. … Return on Equity = Net Profit ÷ Shareholders' Equity
Simply Wall St - – Full articleWant To Invest In OraSure Technologies, Inc. (NASDAQ:OSUR) Today? Read This First
Growth expectations for OraSure Technologies, Inc. … (NASDAQ:OSUR) are high, but many investors are starting to ask whether its last close at $11.07 can still be rationalized by the future potential. … OraSure Technologies is poised for significantly high earnings growth in the near future
Simply Wall St - – Full articleAt US$11.56, Is OraSure Technologies, Inc. (NASDAQ:OSUR) Worth Looking At Closely?
received a lot of attention from a substantial price increase on the NASDAQGS over the last few months. … With many analysts covering the stock, we may expect any price-sensitive announcements have already been factored into the stock’s share price? … Let’s examine OraSure Technologies’s valuation and outlook in more detail to determine if there’s still a bargain opportunity
Simply Wall St - – Full articleHow Much Are OraSure Technologies, Inc. (NASDAQ:OSUR) Insiders Taking Off The Table?
So shareholders might well want to know whether insiders have been buying or selling shares in OraSure Technologies, Inc. … But logic dictates you should pay some attention to whether insiders are buying or selling shares. … The Last 12 Months Of Insider Transactions At OraSure Technologies.
Simply Wall St - – Full articleDoes OraSure Technologies, Inc. (NASDAQ:OSUR) Have A Good P/E Ratio?
We'll look at OraSure Technologies, Inc.'s (NASDAQ:OSUR) P/E ratio and reflect on what it tells us about the company's share price. … OraSure Technologies has a P/E ratio of 34.49, based on the last twelve months. … Price to Earnings Ratio = Price per Share ÷ Earnings per Share (EPS)
Simply Wall St - – Full articleCompany Info
Description
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Its principal products include OraQuick ADVANCE HIV-1/2, OraQuick HIV–1/2, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV, OraQuick Ebola, OraQuick Zika, OraSure QuickFlu Rapid Flu A&B test, OraSure, Oragene DX, Oragene DNA, Oragene RNA, ORAcollect DX, ORAcollect DNA, Performagene, OMNIgene GUT, OMNIgene SPUTUM, OMNIgene VAGINAL, OMNIgene ORAL, GenoFIND, Hemagene, PrepIT, Intercept, MICRO-PLATE DOA assays, Intercept i2, homogeneous DOA assays, and professional and over-the-counter cryosurgical systems. In addition, the company manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome, and animal genetics markets. Further, it provides medical devices for the removal of benign skin lesions by cryosurgery or freezing; immunoassay tests and reagents for insurance risk assessment, substance abuse testing, and forensic toxicology applications; an oral fluid Western blot confirmatory test for confirming positive HIV-1 test; and Q.E.D. rapid point-of-care saliva alcohol test. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians’ offices, and commercial and industrial entities. OraSure Technologies, Inc. was founded in 2000 and is based in Bethlehem, Pennsylvania.
Details
| Name: | OraSure Technologies, Inc. |
| OSUR | |
| Exchange: | NasdaqGS |
| Founded: | 2000 |
| $548,529,125 | |
| 62,050,806 | |
| Website: | http://www.orasure.com |
| Address: |
OraSure Technologies, Inc. 220 East First Street, Bethlehem, Pennsylvania, 18015, United States |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| NasdaqGS | OSUR | Common Stock | Nasdaq Global Select | US | USD | 17. Nov 1986 | |
| DB | EP3 | Common Stock | Deutsche Boerse AG | DE | EUR | 17. Nov 1986 |
Number of employees
Current staff
Industry
| Health Care Supplies | |
| Healthcare |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/06/19 23:41 |
| End of day share price update: | 2019/06/19 00:00 |
| Last estimates confirmation: | 2019/06/17 |
| Last earnings filing: | 2019/05/09 |
| Last earnings reported: | 2019/03/31 |
| Last annual earnings reported: | 2018/12/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
